(CercleFinance.com) – Neovacs announces that new results have been presented on development projects for candidate vaccines in the field of asthma treatment.
These results gave rise to an oral presentation and a poster during the annual Congress of the European Molecular Biology Organization (EMBO / European Molecular and Biology Organization) entitled: Workshop Antibodies and complement: effector functions, therapies and technologies.
‘The work presented bears witness to the significant progress on these two programs (anti-IgE project and IL-4 and IL-13 project) for the treatment of asthma,’ indicates the company.